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a b s t r a c t
Worldwide, resistance of Gram-negative micro-organisms to third-generation cephalosporins and car-
bapenems owing to -lactamases is an increasing problem. Although the CTX-M, TEM and SHVccepted 4 January 2011
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extended-spectrum -lactamases (ESBLs) are most widely disseminated, other -lactamase families
have also recently emerged, such as plasmid-mediated AmpC -lactamases and carbapenemases. Here
we describe a new set of multiplex polymerase chain reactions (PCRs) with one ampliﬁcation protocol
enabling detection of 25 prevalent -lactamase families, including ESBLs, carbapenemases, plasmid-
mediated AmpC -lactamases and OXA -lactamases.
nd th
lasmid-mediated AmpC -lactamases
XA -lactamases
arbapenemases
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. Introduction
The increasing prevalence of Gram-negative bacteria producing
-lactamases, which hydrolyse third-generation cephalosporins
r carbapenems, is a worldwide problem. The most prevalent -
actamases are extended-spectrum -lactamases (ESBLs) of the
TX-M, TEM and SHV families [1]. However, the prevalence of
ram-negative bacteria that are resistant to third-generation
ephalosporins owing to increased expression of chromosomal
-lactamases, such as SME and IMI-1, or the acquisition of plasmid-
ediated -lactamases, such as IMI-2, NDM-1, KPC, IMP, OXA, PER
nd VEB, as well as AmpC -lactamases is increasing [2–6].
Several multiplex polymerase chain reactions (PCRs) for the
etection of -lactamase families have been published [7–9]. In
articular, the set of multiplex PCRs by Dallenne et al. [7] detects a
road range of epidemiologically important -lactamase families.
owever, this set does not detect the SME, IMI, NDM, NMC-A, GIM,
IM and SPM -lactamase families as well as several OXA groups
ithin the OXA family.
The aim of this study was to develop a set of multiplex PCRs
or the detection of the majority of genes encoding clinically
mportant-lactamases causing third-generation cephalosporin or
arbapenem resistance using a single ampliﬁcation protocol.
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To achieve this aim, seven multiplex PCRs were developed for
the detection of plasmid-mediated AmpC -lactamases (ACC, ACT,
DHA, CMY, FOX, LAT, MIR and MOX), metallo-carbapenemases
(GIM, NDM, SIM and SPM), serine carbapenemases (IMI, SME and
NMC-A) and OXA -lactamases (OXA groups 23, 24, 48, 1, 2, 51,
4 and 58) using Super Taq polymerase (HT Biotechnology Ltd.,
Cambridge, UK) (Table 1). For detection of genes encoding CTX-M,
TEM, SHV, GES, VEB, PER, KPC, VIM and IMP -lactamase fam-
ilies, four multiplex PCRs of Dallenne et al. (multiplex I, II, IV
and VI) [7] were evaluated using the same ampliﬁcation proto-
col as used for our PCRs, including Super Taq polymerase instead
of the AmpliTaq polymerase (Sigma-Aldrich, St-Quentin-Fallavier,
France) originally used by the authors.
2. Materials and methods
Primers were designed using the DNASTAR Lasergene 8 pro-
gram (DNASTAR, Madison, WI). Optimisation of the ampliﬁcation
conditions of each PCR, both the newly presented PCRs in this
paper as well as the complementary PCRs of Dallenne et al.
[7], resulted in the following PCR protocol. DNA was isolated
using a NucleoSpin® Tissue Kit (Macherey-Nagel, Dv¨ren, Germany)
according to the manufacturer’s instructions. DNA concentra-
Open access under the Elsevier OA license.tions of the samples were equalised to ca. 50ng/L and 1L
was added to each multiplex PCR in a 25L reaction mixture
containing 1× PCR buffer, 50M of each deoxynucleotide triphos-
phate, 1 U Super Taq and a variable concentration of primers
and MgCl2 (Table 1). Ampliﬁcation was carried out as follows:
ss under the Elsevier OA license.
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Table 1
Group-speciﬁc primers used in the multiplex PCRs.
Multiplex -Lactamase(s) targeteda Primer name Sequence (5′ →3′) Positive control Amplicon
size (bp)
Primer concentration
(pmol/L)
MgCl2 concentration
(mM)
MGA SME-1 to SME-3 SME-GAM-F GAG GAA GAC TTT GAT GGG AGG AT Nord-03 [10] 334 0.8 1.5
SME-GAM-R TCC CCT CAG GAC CGC CAA G 0.7
IMI-1 to IMI-3, NMC-A IMI-GS-F GGT GTC TAC GCT TTA GAC ACT GGC TC Nord-04 [11] 536 0.5
IMI-GS-R GCA CGA ATA CGC GCT GCA CCG G 0.6
MGB GIM-1 GIM-GBM-F CGT TGC CAG CTT TAG CTC AGG PSA098 (this study) 279 0.3 2.5
GIM-GBM-R GCA ACT TGA TAC CAG CAG TGC G 0.3
SIM-1 SIM-GBM-F TTG CGG AAG AAG CCC AGC CAG PSA097 [12] 613 0.3
SIM-GBM-R GCG TCT CCG ATT TCA CTG TGG C 0.3
NDM-1 NDM-GBM-F CCC GGC CAC ACC AGT GAC A NCTC- 13443 129 0.7
NDM-GBM-Rb GTA GTG CTC AGT GTC GGC AT 0.6
SPM-1 SPM-GBM-F GGG TGG CTA AGA CTA TGA AGC C PSA096 [9] 447 1.2
SPM-GBM-R GCC GCC GAG CTG AAT CGG 1.4
MGC1 CMY-1, CMY-8 to CMY-11, CMY-19; MOX-1 to MOX-4 and
[MOX-5 to MOX-7]
CY1-GC1M-F GCT GCT CAA GGA GCA CAG GAT CCC G CP043, CP113 [13] 522 0.5 1.0
CY1-GC1M-R GGC ACA TTG ACA TAG GTG TGG TGC ATG 0.5
DHA-1 to DHA-3, DHA-7 DHA-GC1M-F CTT TCA CAG GTG TGC TGG GTG CG CP039 [13] 403 0.5
DHA-GC1M-R CCG TAC GCA TAC TGG CTT TGC GC 0.6
ACC-1 to ACC-4 ACC-GC1M-F TCC AGC CGC TGA TGC AGA AGA AT CP044 [13] 365 1.1
ACC-GC1M-R CCA YGC TTT TAG ATA AGC CAT CAG CTG 1.0
MGC2 CMY-2-groupc, LAT-1, LAT-4d CY2-GC2M-F ACT GGC CAG AAC TGA CAG GCA AA CP040, CP122, CP168 [13] 466 1.7 1.0
CY2-GC2M-R GTT TTC TCC TGA ACG TGG CTG GC 1.7
ACT-1 to ACT-3, MIR-1 to MIR-4, MIR-8 and [ACT-5]e ACT-GC2M-F TCG GTA AAG CCG ATG TTG CGG CP038 [13] 302 0.6
ACT-GC2M-R CTT CCA CTG CGG CTG CCA GTT 0.6
FOX-1 to FOX-8 FOX-GC2M-F CAT GGG GTA TCA GGG AGA TGC C CP093 [13] 218 0.1
FOX-GC2M-R GCC GCT GCT CGC CCA TCG 0.1
MGD1 OXA-23, -27, -49, -73, -133, -146 O23-GDM-F CCT GAT CGG ATT GGA GAA CCA G NCTC-13421, CP081 [13] 516 0.6 2.0
O23-GDM-R GAT GCC GGC ATT TCT GAC CG 0.7
OXA-24 (= -33, -40), -25, -26, -72, -139, -160 and
[OXA-143, -182]
O24-GDM-F GGT CGA TAA TTT TTG GTT AGT TGG CCC NCTC-13302, NCTC-13303 237 0.3
O24-GDM-R CCA TTA GCT TGC TCC ACC CAA CCA G 0.3
OXA-48, -54 and [OXA-181] O48-GDM-F CCA AGC ATT TTT ACC CGC ATC KAC C NCTC-13442 389 1.1
O48-GDM-R GYT TGA CCA TAC GCT GRC TGC G 1.2
MGD2 OXA-1 (=30), -31, -47 O1-GD2M-F CAA CGG ATT AAC AGA AGC ATG GCT CG CP116 [13] 198 0.1 2.5
O1-GD2M-R GCT GTR AAT CCT GCA CCA GTT TTC CC 0.1
OXA-2, -3, -15, -21, -32, -34, -36, -46, -53, -141, -144, -161
and [OXA-118, -119]
O2-GD2M-F GAC CAA GAT TTG CGA TCA GCA ATG CG CP082, CP087 [13] 256 0.8
O2-GD2M-R CYT TGA CCA AGC GCT GAT GTT CYA CC 0.8
OXA-51 groupf O51-GD2M-F GAC CGA GTA TGT ACC TGC TTC GAC C NCTC-13420 497 1.6
O51-GD2M-R GAG GCT GAA CAA CCC ATC CAG TTA ACC 1.5
MGD3 OXA-10 groupg and [OXA-5] O10-GD3M-F CGC CAG AGA AGT TGG CGA AGT AAG CP089 [13] 138 1.1 2.0
O10-GD3M-R GAA ACT CCA CTT GAT TAA CTG CGG 1.1
OXA-58, -96, -97, -164 O58-GD3M-F GTG CTG AGC ATA GTA TGA GTC GAG C NCTC-13305 630 0.5
O58-GD3M-R GGT CTA CAG CCA TTC CCC AGC C 0.6
PCR, polymerase chain reaction; NCTC, National Collection of Type Cultures.
a All allotypes without brackets have no or one mismatch with the primers, except for the 3′-nucleotide, designed for this target group.
b Primer sequence from David Livermore, Health Protection Agency, UK (pers. corr.).
c CMY-2, -4 to -7, -12 to -16, -18, -21, -23, -24, -27 to -36, -38 to -41, -43 to -45, -47 to -49, -53 to -55, and -59.
d Also known as the EBC group [14].
e Also known as the CIT group [14].
f OXA-51, -64 to -71, -75 to -80, -82 to -84, -86 to -95, -98 to -100, -106 to -113, -115 to -117, -128, -130 to -132, -138, -144, -148 to -150, and -172 to -180.
g OXA-4, -7, -10, -11, -13, -14, -16, -17, -19, -28, -56, -74, -101, -129, -142, -145 and -147.
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Fig. 1. Multiplex polymerase chain reactions (PCRs). All multiplex PCR products were separated on a 1% agarose gel. (A) Multiplex PCR for detection of the carbapenemase
families SME, IMI and NMC-A. Lane M, molecular size marker (in bp); lane 1, Nord-03+Nord-04; lane 2, Nord-03; lane 3, Nord-04; and lane 4, negative control. (B) Lanes
1–5, multiplex PCR for CIT, EBC and FOX groups of plasmid-mediated AmpC -lactamases; lanes 6–10 multiplex PCR for OXA-1, -2 and -51 groups. Lane M, molecular size
marker (in bp); lane 1, CP040+CP038+CP093; lane 2, CP040; lane 3, CP038; lane 4, CP093; lane 5, negative control; lane 6, CP116+CP082+NCTC-13420; lane 7, CP116;
lane 8, CP082; lane 9, NCTC-13420; and lane 10, negative control. (C) Multiplex PCR for detection of the metallo-carbapenemase families SIM, GIM, SPM and NDM. Lane M,
molecular size marker (in bp); lane 1, PSA096+PSA097+PSA098+NCTC-13443; lane 2, PA097; lane 3, PSA098; lane 4, NCTC-13443; lane 5, PSA096; and lane 6, negative
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tontrol. (D) Lanes 1–5, multiplex PCR for OXA-23, -24 and -48 groups; lanes 6–9, m
, CP081+NCTC-13303+NCTC-13442; lane 2, CP081; lane 3, NCTC-13303; lane 4, N
CTC-13305; and lane 9, negative control. (E) Multiplex PCR for CMY-1, MOX, DHA a
in bp); lane 1, CP043+CP039+CP044; lane 2, CP043; lane 3, CP039; lane 4, CP044;
nitial denaturation for 1min at 94 ◦C, 30 cycles of 30 s at 94 ◦C,
0 s at 60 ◦C and 1min at 72 ◦C, and a ﬁnal elongation step for
min at 72 ◦C. Ampliﬁcation products were visualised after run-
ing at 100V for 1h on a 1% agarose gel containing GelRedTM
Biotium Inc., Hayward, CA). A 1-kb DNA ladder (Invitrogen, Breda,
he Netherlands) was used as a size marker. DNA sequenc-
ng was performed by BaseClear (Leiden, The Netherlands). In
ilico PCR simulations were performed using nucleotide BLAST
http://blast.ncbi.nlm.nih.gov/Blast.cgi) and MegAlign (DNASTAR
asergene 8).
. Results and discussion
Ampliﬁcationproducts of the expected sizeswereobtainedwith
ll control strains, conﬁrming the group speciﬁcity of the primers
Fig. 1). In addition, the expected ampliﬁcation products were also
btained with the adapted complementary PCRs described by Dal-
enne et al. [7] (data not shown). To determine the speciﬁcity of the
rimers for allotypes forwhich no positive control strainwas avail-
ble, in silico PCR simulation was performed. All allotypes to which
he primers anneal, allowing for one mismatch except for the 3′-x PCR for OXA-10 and OXA-58 groups. Lane M, molecular size marker (in bp); lane
3442; lane 5, negative control; lane 6, CP089+NCTC-13305; lane 7, CP089; lane 8,
C groups of plasmid-mediated AmpC -lactamases. Lane M, molecular size marker
ne 5, negative control.
nucleotide, and allotypes with more mismatches but in the same
target gene group were identiﬁed (Table 1). In silico PCR simula-
tion was also performed to check for any unwanted cross-reaction
with members of the Enterobacteriaceae, Acinetobacter baumannii
and Pseudomonas aeruginosa. The 3′-end of the SPM-GBM-R primer
anneals with 21 of 27bp to the ACC deaminase gene of a Pseu-
domonas spp. (GenBank accession no. EU520401) and the 3′-end of
O58-GD3M-Rannealswith17of22bp to thebiotin sulfoxide reduc-
tase gene of Escherichia coli (GenBank accession no. CP001846) and
also with 17 of 22bp to the molybdopterin guanine dinucleotide-
containing S/N-oxide reductase gene of E. coli (GenBank accession
no. CP001637). Cross-reaction of the SPM-GBM-R primer was not
a problem with the P. aeruginosa positive control. Cross-reactions
of O58-GD3M-R may result in poorer resolution of the MGD3 mul-
tiplex PCR when used in combination with E. coli.
It should be noted that the MGC2 multiplex PCR yielded a 160-
bp non-speciﬁc ampliﬁcation product (Fig. 1B, lanes 1 and 2). DNA
sequencing showed that thisproductwas identical topart of aCMY-
2 group gene in the control strain (lanes 1 and 2). In six isolates that
were expected to remain negative, another 160-bp non-speciﬁc
ampliﬁcation product was noted. DNA sequencing showed that
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his product was part of an ACT-like AmpC (GenBank accession
o. EF078894.1) (data not shown). The CMY-2 group gene ampli-
cation resulted from annealing of the ACT-GCM2-R primer and
Y2-GC2M-F primer to genes of the CMY-2 group despite several
ismatches. The ACT-like AmpC gene ampliﬁcation resulted from
nnealing of the ACT-GCM2 primers to the ACT-like AmpC gene.
owever, these ampliﬁcation products were not considered to be
problem for interpretation of the multiplex PCR because they
re smaller than the expected speciﬁc products. Furthermore, the
mpliﬁcation products were derived from a CMY-2 group or ACT-
ike gene, which are both targets of the MGC2 multiplex PCR. In
onclusion, we describe a set of multiplex PCRs that, when used in
ombinationwith themultiplexes I, II, IVandVIofDallenneetal. [7],
an detect a wide range of -lactamases using the same ampliﬁca-
ion conditions. This enables detection of the majority of clinically
mportant-lactamases causing third-generation cephalosporin or
arbapenem resistance.
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